Clinical Trials Logo

Carcinoma, Merkel Cell clinical trials

View clinical trials related to Carcinoma, Merkel Cell.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05422781 Completed - Clinical trials for Merkel Cell Carcinoma

Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)

Start date: June 13, 2022
Phase: Phase 1
Study type: Interventional

This Phase I clinical trial will evaluate the safety, tolerability, and immunogenicity of 4 mg doses of ITI-3000 in participants with polyomavirus-positive Merkel cell carcinoma (MCC).

NCT ID: NCT05253144 Completed - Clinical trials for Merkel Cell Carcinoma

Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCC

Rational-MCC
Start date: March 19, 2016
Phase: N/A
Study type: Interventional

A randomised phase III multi-centre trial comparing radical surgery and radical radiotherapy as first definitive treatment for primary MCC

NCT ID: NCT04393753 Completed - Clinical trials for Merkel Cell Carcinoma

Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1

MERKLIN2
Start date: October 13, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with advanced unresectable and/or metastatic Merkel Cell Carcinoma that have progressed on a previous therapy with an anti-PD-(L)1 antibody

NCT ID: NCT03841110 Completed - Colorectal Cancer Clinical Trials

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Start date: February 15, 2019
Phase: Phase 1
Study type: Interventional

FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in participants with advanced solid tumors.

NCT ID: NCT03798639 Completed - Clinical trials for Merkel Cell Carcinoma

Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer

Start date: January 7, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and how well nivolumab works when given together with radiation therapy or ipilimumab as adjuvant therapy in treating patients with Merkel cell cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons or other sources to kill tumor cells and shrink tumors. Giving nivolumab with radiation therapy or ipilimumab after surgery may kill any remaining tumor cells.

NCT ID: NCT03783078 Completed - Clinical trials for Merkel Cell Carcinoma

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

Start date: February 25, 2019
Phase: Phase 3
Study type: Interventional

This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial is to assess the objective response rate, as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, following administration of pembrolizumab.

NCT ID: NCT03652077 Completed - Ovarian Cancer Clinical Trials

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Start date: September 24, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.

NCT ID: NCT03629756 Completed - Breast Cancer Clinical Trials

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Start date: July 24, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with zimberelimab (AB122) (an anti-PD-1 antibody) in participants with advanced malignancies.

NCT ID: NCT03545334 Completed - Malignant Melanoma Clinical Trials

Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study

LIMIT
Start date: September 1, 2017
Phase: N/A
Study type: Interventional

A diagnostic sensitivity study comparing intradermal indocyanine green (ICG) and near infrared fluorescence imaging (NIRFI) with intradermal technetium 99m and traditional lymphoscintigraphy (LS) for transcutaneous identification of sentinel lymph nodes (SLN) in malignant melanoma - a prospective Phase II clinical study in a single center.

NCT ID: NCT03538028 Completed - Ovarian Cancer Clinical Trials

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Start date: June 18, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.